Mansoor Mirza, MD, chief oncologist, Department of Oncology, Copenhagen University Hospital, discusses the findings from NSGO-AVANOVA2/ENGOT-OV24, the randomized controlled chemotherapy-free study of niraparib (Zejula) and bevacizumab (Avastin) versus niraparib alone in recurrent platinum-sensitive ovarian cancer.

Related Content

Vigil Immunotherapy Prolongs RFS as Frontline Maintenance Treatment in Ovarian Cancer

April 14, 2020 12:00am

By Gina Columbus

Frontline Niraparib Plus Bevacizumab for Advanced Ovarian Cancer Yields Promising Activity

April 13, 2020 07:00pm

By Gina Columbus

Analyses of Frontline Niraparib Maintenance Demonstrate Positive Patient-Reported Outcomes in Ovarian Cancer

April 11, 2020 10:00pm

By Jason M. Broderick

More Frontline PARP Indications Are Expected in Ovarian Cancer

November 08, 2019 03:38am

By Audrey Sternberg